Oncotelic publishes study showing TGF-β2 predicts poor survival in DIPG; OT-101 protocol accepted by NIHR

Oncotelic Therapeutics, Inc.

Publication in Cancers shows high intra-tumor TGF-β2 level predicts poor survival in pediatric brainstem cancer (DIPG).
TGFβ1 and TGFβ3 isoforms are also predictive; OT-101 is the only TGFβ2 inhibitor in late clinical development.
Clinical study protocol for OT-101 in pediatric brainstem cancer accepted onto UK NIHR portfolio.
CEO states targeting TGFβ2 could rectify previous clinical failures such as bintrafusp alfa.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.